v-2.jpg
logo-1-new.png

About Us

Amytrx is a clinical-stage biopharmaceutical company advancing the next generation of new anti-inflammatory peptide therapies for patients suffering from chronic inflammatory diseases. We are a group of dedicated scientific, medical, and business professionals all deeply committed to positively transforming the health and lives of patients.  

Leadership Team

Matthew A. Gonda, Ph.D.

President, CEO and Founder

Randall B. Riggs, MBA

Chief Business Officer

Shima Joshi, Ph.D.

VP, Regulatory Affairs

Vernon L. Alvarez, Ph.D.

SVP, Research & Development

Satish Joshi, Ph.D.

VP, Peptide Chemistry

Maya Frutiger

VP, Corporate Affairs

Danny O. Helton, Ph.D.

VP, Chemistry & Manufacturing

Board of Directors 

Matthew A. Gonda, Ph.D.

President, CEO and Founder

Lawrence W. Greer, DDS, MBA

Director

G. William Coble, II

Director

Daniel D. Canale, M.D.

Director

Thomas G. Andrews

Director and Founder

Dennis J. Carlo, Ph.D.

Director

Raymond Pirtle, Jr.

Director

Founders

Matthew A. Gonda, Ph.D.

President, CEO and Founder

Thomas G. Andrews

Director and Founder

Jacek Hawiger, M.D., Ph.D.

Founder

logo.png

Amytrx Therapeutics, Inc.

102 Woodmont Blvd | Suite 243 Nashville, TN 37205

400 Riverhill Business Park | Suite 410 Birmingham, AL 35242

Copyright © 2020  All Rights Reserved.